Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announced that CEO and Chairman John Yu, MD, will present a corporate overview in person at the H.C. Wainwright 28th Annual Global Investment Conference, taking place Sept. 14-16, 2026, at the Lotte New York Palace Hotel. The presentation is expected to highlight the company's innovative approach to oncology therapeutics and its lead candidate, ENV-105.
The significance of this presentation lies in the opportunity for Kairos Pharma to showcase its scientific platform to a broad investment audience. H.C. Wainwright conferences are known for attracting institutional investors, analysts, and industry leaders, providing a key venue for emerging biopharmaceutical companies to gain visibility and potentially secure funding. For Kairos, this is a chance to articulate how its technology addresses a critical unmet need in cancer treatment: drug resistance.
Kairos Pharma is based in Los Angeles, California, and utilizes structural biology to design therapies that overcome drug resistance and immune suppression. Its lead candidate, ENV-105, is an antibody that targets CD105, a protein identified as a key driver of resistance and disease relapse following standard therapy. By targeting CD105, ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. This mechanism has the potential to significantly improve patient outcomes in cancers that currently have limited options after resistance develops.
The company's focus on CD105 is particularly relevant given the growing understanding of the tumor microenvironment's role in therapy failure. CD105 is expressed on proliferating endothelial cells and is involved in angiogenesis, but recent research has linked it to resistance mechanisms in various solid tumors. Kairos's approach could offer a new strategy for combination therapies, potentially extending the durability of existing treatments.
Investors and industry observers will be watching closely to see if the company presents new data or outlines next steps for ENV-105's clinical development. The presentation at such a prestigious conference often serves as a platform for companies to announce milestones, partnerships, or trial updates. Any such news could have a material impact on the company's stock price and its positioning within the oncology space.
For more information about Kairos Pharma and its pipeline, interested parties can visit the company's newsroom at https://ibn.fm/KAPA.
The full press release detailing the conference presentation is available at https://ibn.fm/NrBQD.
